Placeholder Banner

BIO Comments on FDA Draft Guidance on ANDAs for Certain Highly Purified Synthetic Peptide Drug Products Referring to Listed Drugs of rDNA Origin

February 4, 2017

BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin.

BIO supports enhanced regulatory guidance on considerations for approval of generic and follow-on medicine products, as well as the FDA’s recognition of the appropriateness of the 505(b)(2) application for regulatory assessment of generic medicines and follow-on peptide products.

However, BIO requests FDA provide greater scientific reasoning and specificity on its analysis for the sweeping determination that an ANDA submission may be appropriate for the five specific peptides referenced the guidance. BIO’s comments address this concern in more detail.

Download Full Comments Below
BIO Letter ANDA For Synthetic Peptides 2-2-18
Read full comment letter below
Discover More
On Wednesday, December 23rd, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s October 2020 public workshop titled, “New Drugs Regulatory Program Modernization: Implementation of the Integrated Assessment of Marketing…
The Biotechnology Innovation Organization (BIO) submits these comments in response to the U.S. Environmental Protection Agency’s (EPA) request for public input on proposed revisions to regulations related to the oversight of certain plant…
Innovative breakthroughs can secure our nation’s food supply by reducing greenhouse gas emissions throughout agricultural supply chains; strengthening producers’ resiliency to climate change while increasing production; and tackling hunger and…